Medarex stiger 12% på en Preklinisk data ??, det lyder godt nok temelig heftigt
Medarex (MEDX) Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer.
"Medarex, Inc. (Nasdaq: MEDX) announced preclinical efficacy and safety data from multiple programs, including antibodies to novel and potentially important cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, CD70) and additional research in the area of antibody-drug conjugates. Data from the studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), April 18-22, 2009, in Colorado."
Medarex (MEDX) Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer.
"Medarex, Inc. (Nasdaq: MEDX) announced preclinical efficacy and safety data from multiple programs, including antibodies to novel and potentially important cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, CD70) and additional research in the area of antibody-drug conjugates. Data from the studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), April 18-22, 2009, in Colorado."
23/4 2009 00:10 tumult 0
8576 Det lyder mærkeligt, det var kendt i går:
http://www.nyse.com/interface/jsp/NHDetail.jsp?RequestID=2&pageID=NewsHeadlines&sid=PR%2004/21%202722&isdowjones=false
Har det mon nogen indflydelse på Genmab. ?
http://www.nyse.com/interface/jsp/NHDetail.jsp?RequestID=2&pageID=NewsHeadlines&sid=PR%2004/21%202722&isdowjones=false
Har det mon nogen indflydelse på Genmab. ?
23/4 2009 00:17 lefthand 08577 Her er et link til hvad det er for data :
http://www.lifesciencesworld.com/news/view/102575
det er en længere smører
http://www.lifesciencesworld.com/news/view/102575
det er en længere smører
23/4 2009 13:25 tumult 08604 Det lader ikke til at Genmab kan bryde MA50, skulle man tage gevinsten.?
